Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Published Online
on January 31, 2008

Stroke. 2008
Published online before print January 31, 2008, doi: 10.1161/STROKEAHA.107.490599
A more recent version of this article appeared on March 1, 2008
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
39/3/1000    most recent
STROKEAHA.107.490599v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sun, L.
Right arrow Articles by Veltkamp, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sun, L.
Right arrow Articles by Veltkamp, R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*OXYGEN
Related Collections
Right arrow Animal models of human disease
Right arrow Acute Cerebral Infarction

Submitted on April 9, 2007
Revised on July 17, 2007
Accepted on August 2, 2007

Hyperbaric Oxygen Reduces Tissue Hypoxia and Hypoxia-Inducible Factor-1{alpha} Expression in Focal Cerebral Ischemia

Li Sun MD; Hugo H. Marti MD; and Roland Veltkamp MD*

From the Departments of Neurology (L.S., R.V.) and Physiology (H.H.M.), Ruprecht-Karls-University Heidelberg, Heidelberg, Germany.

* To whom correspondence should be addressed. E-mail: roland.veltkamp{at}med.uni-heidelberg.de.

Background and Purpose—The usefulness of hyperbaric oxygen (HBO) and normobaric hyperoxia in acute ischemic stroke is being reexplored because both improve outcome in experimental cerebral ischemia. However, even the basic mechanisms underlying oxygen therapy are poorly understood. We investigated the effect of both oxygen therapies on tissue hypoxia and on the transcription factor hypoxia-inducible factor-1{alpha}.

Methods—Mice were subjected to filament-induced middle cerebral artery occlusion for 2 hours. Twenty-five minutes after filament introduction, mice breathed normobaric air, normobaric 100% O2 (normobaric hyperoxia), or 100% O2 at 3 ata (HBO) for 95 minutes. Hypoxic regions were mapped on tissue sections after preischemic infusion of the in vivo hypoxia marker EF-5. Hypoxia-inducible factor-1{alpha} protein was measured after 2-hour middle cerebral artery occlusion using immunofluorescence and immunoblotting. Vascular endothelial growth factor expression was analyzed using in situ mRNA hybridization.

Results—Severity of ischemia did not differ among groups. HBO (35.2±10.4 mm2) significantly reduced the area of EF-5-stained hypoxic regions in focal cerebral ischemia compared with normobaric hyperoxia (46.4±11.2 mm2) and air (49.1±8 mm2, P<0.05, analysis of variance). Topographically, EF-5 fluorescence was decreased in medial striatum and in cortical ischemic border areas. Immunohistochemistry and immunoblotting revealed lower hypoxia-inducible factor-1{alpha} protein in the ischemic hemisphere of HBO-treated mice. Moreover, mRNA in situ hybridization showed lower expression of vascular endothelial growth factor in HBO and normobaric hyperoxia groups.

Conclusions—Measurement of extrinsic and intrinsic markers of hypoxia revealed that HBO improves penumbral oxygenation in focal ischemia. Modification of the transcription factor hypoxia-inducible factor-1{alpha} and its downstream targets may be involved in effects of HBO.


Key words: cerebral ischemia • EF-5 • HBO • hypoxia-inducible factor-1{alpha} • VEGF